Skip to main content

Go Premium in Our Biggest Sale Ever

UPGRADE NOW
TipRanks
Go Ultimate75% OFF

Protagonist Therapeutics (PGF) Stock Price & Analysis

1 Followers

PGF Stock Chart & Stats

€75.00€0.00(0.00%)
At close: 5:30 PM GMT+1
€64€66€68Oct 13Oct 22
Day’s Range
EUR 74.50 - EUR 75.00
52-Week Range
EUR 71.50 - EUR 81.00
Previous Close
EUR 75.00
Volume
N/A
Average Volume (3M)
0
Market Cap
EUR 7.96B
Enterprise Value
EUR 9.31B
Total Cash (Recent Filing)
EUR 800.06M
Total Debt (Recent Filing)
EUR 8.63M
Price to Earnings (P/E)
26.4
Beta
0.18
Next Earnings
Mar 02, 2027 (Est.)
EPS Estimate
-0.13
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Strong TTM Revenue And Profitability

The sharp TTM improvement in revenue and profitability indicates that partnered program activity can generate substantial economic value when milestones or collaboration revenues are recognized. If operating performance remains strong, high margins could support continued research investment and strengthen funding flexibility.

Positive Cash Generation

Positive operating and free cash flow provides internal funding for clinical development and reduces reliance on external capital in the near term. Cash conversion slightly above net income also supports the quality of reported earnings, giving the company greater flexibility across development priorities.

Conservative Balance Sheet

Minimal leverage and a substantial equity base give Protagonist meaningful financial flexibility as it advances peptide-based medicines. The conservative capital structure limits interest and refinancing pressure, allowing more resources to remain available for clinical programs, partnerships, and other long-term priorities.

Bears Say

Revenue And Earnings Volatility

The substantial year-to-year swings show that current profitability is not yet a consistently demonstrated operating trend. Because biotech results can depend on the timing of collaboration and development milestones, uneven earnings make future cash generation and resource planning less predictable over the next several periods.

Limited Cash-flow Consistency

Although recent cash generation is positive, the decline in TTM free cash flow and history of negative cash flow indicate that internally generated funding may not remain stable. This variability can complicate clinical investment planning and increase sensitivity to the timing of partnership-related receipts.

Dependence On Collaboration-based Revenue

The collaboration-led model exposes revenue to the timing and progress of partnered clinical programs rather than a recurring commercial product base. Payments may be uneven because upfront, milestone, and royalty streams depend on development, regulatory, and commercialization achievements.

Protagonist Therapeutics News

PGF FAQ

What was Protagonist Therapeutics’s price range in the past 12 months?
Protagonist Therapeutics lowest stock price was €71.50 and its highest was €81.00 in the past 12 months.
What is Protagonist Therapeutics’s market cap?
Protagonist Therapeutics’s market cap is €7.96B.
When is Protagonist Therapeutics’s upcoming earnings report date?
Protagonist Therapeutics’s next earnings report is estimated for Mar 02, 2027 (not yet confirmed), which is in 111 days.
How were Protagonist Therapeutics’s earnings last quarter?
Protagonist Therapeutics released its earnings results on Nov 05, 2026. The company reported €2.749 earnings per share for the quarter, beating the consensus estimate of €2.743 by €0.005.
Is Protagonist Therapeutics overvalued?
According to Wall Street analysts Protagonist Therapeutics’s price is currently Undervalued.
Does Protagonist Therapeutics pay dividends?
Protagonist Therapeutics does not currently pay dividends.
What is Protagonist Therapeutics’s EPS estimate?
Protagonist Therapeutics’s EPS estimate is -0.13.
How many shares outstanding does Protagonist Therapeutics have?
Protagonist Therapeutics has 65,270,110 shares outstanding.
What happened to Protagonist Therapeutics’s price movement after its last earnings report?
Protagonist Therapeutics reported an EPS of €2.749 in its last earnings report, beating expectations of €2.743. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Protagonist Therapeutics?
Hedge funds hold Protagonist Therapeutics shares: the largest hedge-fund position in Protagonist Therapeutics is 2,061,446,670 shares, and hedge funds decreased their holdings by 214.0K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology